#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Shprintzen-Goldberg syndrome Anti-glomerular basement membrane disease Myotonia Salivary gland cancer Parkinson's disease Cerebral amyloid angiopathy Cognitive disorder Burkitt's lymphoma Acute myeloid leukaemia Osteosarcoma recurrent Pustular psoriasis Acquired ATTR amyloidosis Inflammatory myofibroblastic tumour Adrenocortical carcinoma Glioblastoma multiforme More trials…

    Learn about Rare Diseases

    Amyotrophic lateral sclerosis – Life with Disease Combined immunodeficiency – Diagnostics Idiopathic pulmonary fibrosis Alexander disease – Treatment Synovial sarcoma recurrent – Treatment Pelizaeus-Merzbacher disease – Diagnostics Gaucher’s disease type I – Life with Disease Factor VIII deficiency – Life with Disease Glycogen storage disease type V – Diagnostics Small intestine leiomyosarcoma – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Mitapivat Minocycline Pentixather GOCATAMIG Regn7508 Riliprubart M1P Dipotassium Salt Metoclopramide HTL0022537 Terlipressin Acetate Ace Inhibitors, Plain Mps-214 Relebactam Danicopan SODIUM IBANDRONATE Lsta1 Treosulfan Calcium Levofolinate Obeticholic Acid Calcium Chloride More therapies…

    Learn about Your Condition

    Systemic infection Streptococcal infection Hand fracture Oral neoplasm Splenic marginal zone lymphoma Hepatic angiosarcoma Psychotic behaviour Adrenoleukodystrophy Infertility male Coronary artery occlusion Organ donor Skin wrinkling Muscle injury Facial paresis Retinopathy proliferative More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Psoriasis

  • Study on Long-Term Safety and Efficacy of Deucravacitinib for Patients with Moderate-to-Severe Plaque Psoriasis

    Not recruiting

    3 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Deucravacitinib
    Czechia Finland France Germany Hungary Poland +2

  • Study on the Safety, Effectiveness, and Blood Movement of Bimekizumab in Adolescents with Moderate to Severe Plaque Psoriasis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Bimekizumab
    Germany Poland

  • Study on the Effects of JNJ-81241459 for Patients with Moderate to Severe Psoriasis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Jnj-81241459
    France Germany Poland Spain

  • Study on Guselkumab for Patients with Moderate-to-Severe Plaque Psoriasis

    Not recruiting

    3 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Guselkumab
    Germany

  • Study on Adjustable Brodalumab Dosage for Patients with Moderate-to-Severe Plaque Psoriasis Weighing 120 kg or More

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Brodalumab
    Belgium Czechia France Germany Greece Hungary +3

  • Study Comparing Risankizumab and Deucravacitinib for Adults with Moderate Plaque Psoriasis Eligible for Systemic Therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Deucravacitinib
    • Risankizumab
    Belgium Germany Greece Hungary Italy The Netherlands +1
Previous Page
1 … 5 6 7 8 9
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!